Entity

Time filter

Source Type


Bouchaert P.,Service dOncologie Medicale | Jardel P.,Service de radiotherapie | Osdoit S.,Service de Dermatologie allergologie | Bodard A.-G.,Center Leon Berard | And 4 more authors.
Oncologie | Year: 2011

Due to its high prevalence and potential severity, oropharyngeal candidiasis represents an important issue in oncology. This article deals with the pathophysiology of this infection and the diagnostic strategy, showing different clinical features, differential diagnosis and useful paraclinical examinations. © Springer-Verlag France 2011. Source


Elfatoiki F.Z.,Service de Dermatologie Venerologie | Benchikhi H.,Service de Dermatologie Venerologie | Zouhair K.,Service de Dermatologie Venerologie | Frances C.,Service de Dermatologie allergologie | And 2 more authors.
Nouvelles Dermatologiques | Year: 2012

Arndt-Gottron scleromyxedema is rare disease that usually associated benign monoclonal gammapathy. We report the case of Arndt-Gottron scleromyxedema associated with a circulating monoclonal IgG, in a 51-year-old Moroccan man, treated successfully by intravenous immunoglobulin. © Nouv Dermatol 2012. Source


Peris K.,Catholic University of Rome | Stockfleth E.,Charite - Medical University of Berlin | Gupta G.,Monklands Hospital | Aractingi S.,Service de Dermatologie allergologie | And 5 more authors.
Journal of the European Academy of Dermatology and Venereology | Year: 2015

Background Imiquimod 3.75% reduces 92.2% of all actinic keratosis (AK) lesions, assumed to include both subclinical and clinical lesions, across a large sun-exposed field such as the full face or balding scalp. Objective To evaluate the efficacy of imiquimod 3.75% using the reduction in lesions from Lmax (the maximum lesion count during treatment) in subgroups of patients with low and high AK lesion counts. Methods Patients from two 14-week, placebo-controlled, double-blind studies were subgrouped according to whether they had ≤10 or >10 AK lesions at baseline. Treatment was applied to the full face or balding scalp during two 2-week treatment cycles separated by a 2-week treatment-free interval. Results Overall, 167 patients had ≤10 lesions and 152 patients had >10 AK lesions at baseline. With imiquimod 3.75%, the median percentage reduction in AK lesions from Lmax to end of study was similar in patients with ≤10 and >10 baseline lesions (91.5% and 93.0% respectively). The median absolute reduction in AK lesions from Lmax to end of study was 24.0 for patients with >10 baseline lesions and 10.0 for those with ≤10 baseline lesions. The median percentage and absolute reductions in lesions from Lmax were significantly greater with imiquimod 3.75% vs. placebo (P < 0.0001). Conclusions Imiquimod 3.75% is effective regardless of disease severity as shown in this study by the reduction of over 90% of lesions from Lmax in patients with low or high AK lesion counts. © 2014 European Academy of Dermatology and Venereology. Source


Gupta G.,Monklands Hospital | Stockfleth E.,Charite - Medical University of Berlin | Peris K.,Catholic University of Rome | Aractingi S.,Service de Dermatologie allergologie | And 5 more authors.
Journal of the European Academy of Dermatology and Venereology | Year: 2015

Background In patients with actinic keratosis (AK), subclinical and clinical lesions coexist across large areas of sun-exposed skin. The long-term efficacy of AK treatments depends on their ability to eradicate both types of lesions across the entire field. Objective To assess the long-term efficacy of imiquimod 3.75% using the reduction in lesions from Lmax (maximum lesion count during treatment), which assesses the ability to clear subclinical and clinical lesions. Methods Patients with 5-20 AK lesions on the full face or balding scalp from two 14-week, randomized, vehicle-controlled, double-blind studies of imiquimod 3.75% (daily for two 2-week treatment cycles separated by a 2-week treatment-free period) were eligible to enter a 12-month follow-up study if they had no AK lesions at Week 14. Lesion reduction from Lmax was calculated at 6 and 12 months during follow-up. Results The 42 patients in this long-term study had a median of nine baseline lesions and a median Lmax of 22 lesions. At 6 and 12 months of follow-up, the median absolute reduction in AK lesions from Lmax with imiquimod 3.75% was 21 and 19, respectively. The median percentage reduction in lesions from Lmax to 6 and 12 months was 100% and 97.2%, respectively. Conclusions The ability of imiquimod 3.75% to eliminate clinical and subclinical lesions across an entire sun-exposed field translates into sustained long-term efficacy. Imiquimod 3.75% may therefore represent a first-choice treatment for patients with AK. © 2014 European Academy of Dermatology and Venereology. Source


Weber I.,Service de Dermatologie allergologie | Olaiwan A.,Service de Dermatologie allergologie | Bonte I.,Service de dermatologie | Pras-Landre V.,Pharmacovigilance | And 3 more authors.
European Journal of Dermatology | Year: 2011

Bisphosphonates are frequently used to treat bone diseases characterized by increased osteoclastic bone resorption. Adverse skin reactions to bisphosphonates are rare and range from benign to severe. Different cutaneous skin reactions have been reported with ibandronate in clinical and pharmacovigilance studies, from macula-papular rashes to toxic epidermal necrolysis. We report two new cases of erythematous and oedematous skin lesions to oral monthly ibandronate, appearing after multiple intakes of the drug. Prick tests were positive in both cases at 48 or 96 hours, and one could be confirmed histologically. Lesions did not relapse after substituting the culprit bisphosphonate with another one. A wide range of rare-to-very-rare adverse skin reactions exist with bisphosphonates, and especially ibandronate.We review the reported cases of adverse cutaneous drug reactions to bisphosphonates and illustrate the polymorphism and variety of the skin lesions. These reactions are not well known and may be misdiagnosed as they do not always suggest drug-induced eruptions. Furthermore, delays between drug intake and the first lesions can be misleading. The absence of cross-reactions among bisphosphonates allows substitution. Source

Discover hidden collaborations